Understanding how NLRP3 affects treatment resistance in melanoma
Official title: To Elucidate the Biological Function and Translational Potential of NLRP3 in Immunotherapy-resistant Melanoma
Funded at VA Eastern Colorado Health Care System · NIH-11063219 · Data updated 2026-11-12
This study is looking at how a specific part of the immune system affects melanoma in patients, especially veterans who struggle with current treatments, to find new ways to help them respond better to therapy.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | VA Eastern Colorado Health Care System NIH-funded |
| Lab location | 1 site (Aurora, UNITED STATES) |
| Project start | April 1, 2024 |
| Project end | March 31, 2029 |
| Funding year | 2025 |
| NIH project number | 5IK2BX006147-02 |
| Project ID | NIH-11063219 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include veterans and other individuals with advanced melanoma who have not responded to standard immunotherapy treatments.
✕Less likely to help
Patients with early-stage melanoma or those who have responded well to existing immunotherapy treatments may not benefit from this research.
What this research studies
This research investigates the role of NLRP3 in melanoma, particularly in patients who do not respond well to current immunotherapy treatments. By focusing on the inflammatory processes that contribute to melanoma progression, the study aims to uncover new therapeutic strategies that could improve outcomes for patients, especially veterans who are disproportionately affected by this disease. The research will involve analyzing tumor samples and patient data to identify how inflammation influences treatment resistance and exploring potential interventions targeting these pathways.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options for melanoma patients who currently have limited responses to existing therapies.
How similar studies have gone: While the approach of targeting inflammatory pathways in melanoma is gaining interest, this specific investigation into NLRP3 is relatively novel and has not been extensively tested in prior studies.
Where this research is happening
-
VA Eastern Colorado Health Care System
Aurora, United States Active
Researchers
- Principal investigator: Marchetti, Carlo — VA Eastern Colorado Health Care System
- Study coordinator: Marchetti, Carlo
Related research
Other NIH-funded projects on the same topics.
-
Overcoming Melanoma Treatment Resistance with a Special IL-18 Approach
A Yale-led project tests a special engineered IL-18 immune signal to help melanoma patients who don’t fully respond to current therapies.
-
Prebiotic diet to boost gut health and improve immunotherapy response in melanoma
A diet-based approach using prebiotic foods and nutrition counseling is studied alongside standard immunotherapy to help melanoma patients respond better and reduce side effects.
-
New approach to overcome resistance to immunotherapy in melanoma
A new strategy targets a key pathway in melanoma to boost the effectiveness of immune-based therapies for patients whose cancer resists treatment.
-
Multivalent circular mRNA vaccines for melanoma immunotherapy
A cancer vaccine approach using tiny circular mRNA vaccines aimed at boosting immune responses against melanoma in combination with existing immunotherapies.
-
Lymph Node–Targeted Co-delivery for Melanoma Immunotherapy
Aimed at improving melanoma treatment, this project tests a targeted vaccine approach that helps the body’s immune system better attack skin cancer.
-
Multifunctional nanoparticles to boost melanoma immunotherapy
A new nanoparticle approach using ultrasound-triggered systems aims to make melanoma immunotherapy work better for patients who don’t respond well to current treatments.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.